Consolidated Statements of Changes in Shareholders' Deficit - USD ($) shares in Millions, $ in Millions | Total | Cumulative effect adjustment | Common Stock | Additional Paid-in Capital | Retained Earnings (Losses) | Retained Earnings (Losses)Cumulative effect adjustment | Accumulated Other Comprehensive Loss | Treasury Stock | Noncontrolling Interest |
Beginning balance (in shares) at Dec. 31, 2019 | | | | 770 | | | | | 319.9 | |
Beginning balance at Dec. 31, 2019 | | $ (983.8) | $ (2) | $ 192.6 | $ 2,321.2 | $ 2,138.9 | $ (2) | $ (1,040) | $ (4,603.3) | $ 6.8 |
Increase (Decrease) in Stockholders' Equity [Roll Forward] | | | | | | | | | | |
Net loss | | (171.9) | | | | (171) | | | | (0.9) |
Other comprehensive income (loss) | | (104.5) | | | | | | (104.3) | | (0.2) |
Conversion of Series C convertible preferred stock | [1] | 486.8 | | | | (710.8) | | | $ 1,197.6 | |
Conversion of Series C convertible preferred stock (in shares) | [1] | | | | | | | | (87) | |
Exercise/ vesting/ expense of share-based compensation | | (9.9) | | $ (0.2) | (9.7) | | | | | |
Exchange of common stock (in shares) | [2] | | | (770) | | | | | (232.9) | |
Exchange of common stock | [2] | 0 | | $ (192.4) | (1,788.1) | (1,425.2) | | | $ 3,405.7 | |
Ending balance (in shares) at Mar. 31, 2020 | | | | 0 | | | | | 0 | |
Ending balance at Mar. 31, 2020 | | (785.3) | | $ 0 | 523.4 | (170.1) | | (1,144.3) | $ 0 | 5.7 |
Beginning balance (in shares) at Dec. 31, 2019 | | | | 770 | | | | | 319.9 | |
Beginning balance at Dec. 31, 2019 | | (983.8) | $ (2) | $ 192.6 | 2,321.2 | 2,138.9 | $ (2) | (1,040) | $ (4,603.3) | 6.8 |
Increase (Decrease) in Stockholders' Equity [Roll Forward] | | | | | | | | | | |
Net loss | | (298.9) | | | | | | | | |
Other comprehensive income (loss) | | (126.9) | | | | | | | | |
Ending balance (in shares) at Sep. 30, 2020 | [3] | | | 0 | | | | | 0 | |
Ending balance at Sep. 30, 2020 | [3] | (929) | | $ 0 | 527.7 | (294.3) | | (1,166.9) | $ 0 | 4.5 |
Beginning balance (in shares) at Mar. 31, 2020 | | | | 0 | | | | | 0 | |
Beginning balance at Mar. 31, 2020 | | (785.3) | | $ 0 | 523.4 | (170.1) | | (1,144.3) | $ 0 | 5.7 |
Increase (Decrease) in Stockholders' Equity [Roll Forward] | | | | | | | | | | |
Net loss | | (93.5) | | | | (92.8) | | | | (0.7) |
Other comprehensive income (loss) | | (1.5) | | | | | | (1.5) | | |
Exercise/ vesting/ expense of share-based compensation | | 0.8 | | | 0.8 | | | | | |
Ending balance (in shares) at Jun. 30, 2020 | | | | 0 | | | | | 0 | |
Ending balance at Jun. 30, 2020 | | (879.5) | | $ 0 | 524.2 | (262.9) | | (1,145.8) | $ 0 | 5 |
Increase (Decrease) in Stockholders' Equity [Roll Forward] | | | | | | | | | | |
Net loss | | (33.5) | | | | (32.8) | | | | (0.7) |
Gain on common control transaction | | 1.4 | | | | 1.4 | | | | |
Other comprehensive income (loss) | | (20.9) | | | | | | (21.1) | | 0.2 |
Exercise/ vesting/ expense of share-based compensation | | 3.5 | | | 3.5 | | | | | |
Ending balance (in shares) at Sep. 30, 2020 | [3] | | | 0 | | | | | 0 | |
Ending balance at Sep. 30, 2020 | [3] | (929) | | $ 0 | 527.7 | (294.3) | | (1,166.9) | $ 0 | 4.5 |
Beginning balance (in shares) at Dec. 31, 2020 | | | | 0 | | | | | | |
Beginning balance at Dec. 31, 2020 | | (867.2) | | $ 0 | 622.8 | (360.5) | | (1,133.8) | | 4.3 |
Increase (Decrease) in Stockholders' Equity [Roll Forward] | | | | | | | | | | |
Net loss | | (63.9) | | | | (63.6) | | | | (0.3) |
Other comprehensive income (loss) | | (43.3) | | | | | | (43.3) | | |
Exercise/ vesting/ expense of share-based compensation | | 0.6 | | | 0.6 | | | | | |
Ending balance (in shares) at Mar. 31, 2021 | | | | 0 | | | | | | |
Ending balance at Mar. 31, 2021 | | (973.8) | | $ 0 | 623.4 | (424.1) | | (1,177.1) | | 4 |
Beginning balance (in shares) at Dec. 31, 2020 | | | | 0 | | | | | | |
Beginning balance at Dec. 31, 2020 | | (867.2) | | $ 0 | 622.8 | (360.5) | | (1,133.8) | | 4.3 |
Increase (Decrease) in Stockholders' Equity [Roll Forward] | | | | | | | | | | |
Net loss | | (169.1) | | | | | | | | |
Other comprehensive income (loss) | | (19.9) | | | | | | | | |
Ending balance (in shares) at Sep. 30, 2021 | [4] | | | 0 | | | | | | |
Ending balance at Sep. 30, 2021 | [4] | (898.5) | | $ 0 | 632.1 | (379.8) | | (1,153.5) | | 2.7 |
Beginning balance (in shares) at Mar. 31, 2021 | | | | 0 | | | | | | |
Beginning balance at Mar. 31, 2021 | | (973.8) | | $ 0 | 623.4 | (424.1) | | (1,177.1) | | 4 |
Increase (Decrease) in Stockholders' Equity [Roll Forward] | | | | | | | | | | |
Net loss | | (62.1) | | | | (61.6) | | | | (0.5) |
Other comprehensive income (loss) | | 32.2 | | | | | | 32.1 | | 0.1 |
Exercise/ vesting/ expense of share-based compensation | | 4.2 | | | 4.2 | | | | | |
Ending balance (in shares) at Jun. 30, 2021 | [4] | | | 0 | | | | | | |
Ending balance at Jun. 30, 2021 | [4] | (999.5) | | $ 0 | 627.6 | (485.7) | | (1,145) | | 3.6 |
Increase (Decrease) in Stockholders' Equity [Roll Forward] | | | | | | | | | | |
Sale of Avon Luxembourg | [5] | 148.4 | | | | 148.4 | | | | |
Net loss | | (43.1) | | | | (42.5) | | | | (0.6) |
Other comprehensive income (loss) | | (8.8) | | | | | | (8.5) | | (0.3) |
Exercise/ vesting/ expense of share-based compensation | | 4.5 | | | 4.5 | | | | | |
Ending balance (in shares) at Sep. 30, 2021 | [4] | | | 0 | | | | | | |
Ending balance at Sep. 30, 2021 | [4] | $ (898.5) | | $ 0 | $ 632.1 | $ (379.8) | | $ (1,153.5) | | $ 2.7 |
| |
[1] | On December 30, 2019, an affiliate of Cerberus Capital Management, L.P. ("Cerberus") elected to convert 435,000 shares of Series C Preferred Stock into 87,000,000 shares of the Company’s common stock, par value U.S.$0.25 per share, conditioned on the Conversion Condition (as defined below). | |
[2] | In January 2020, subsequent to the Transaction, the Company restated its certificate of incorporation to effect a change in capitalization of the Company by changing the number of authorized shares of common stock from 1,525,000,000 shares (of which (i) 1,500,000,000 shares, par value $0.25 per share, were common stock and (ii) 25,000,000 shares, par value $1.00 per share, were preferred stock) to 1,000 shares of common stock, par value $0.01 per share. As a result of the Transaction, all of the issued and outstanding common stock of the Company, being 550,890,788, were canceled and converted. See Note 17, Mergers with Natura Cosméticos S.A. | |
[3] | The number of shares of Common Stock (par value $0.01 per share) outstanding at September 30, 2020 was 101.34. | |
[4] | The number of shares of Common Stock (par value $0.01 per share) outstanding at September 30, 2021 was 101.34. | |
[5] | On July 1, 2021, the Company sold Avon Luxembourg Holdings S.à r.l. and its subsidiaries ("Avon Luxembourg"), including our Mexican business, to a subsidiary of Natura &Co Holding S.A. for $150. The sale was accounted for as a transaction under common control in accordance with ASC805 - Business Combinations, with the resulting gain of $148, representing the difference between the proceeds, the net assets of Avon Luxembourg on the date of sale, and the cumulative foreign currency translation adjustment, taken directly to Retained Earnings. | |